Vemurafenib
Klinički podaci
AHFS/Drugs.com
Monografija
Identifikatori
CAS broj
918504-65-1
ATC kod
L01 XE15
PubChem [ 1] [ 2]
42611257
DrugBank
DB08881
ChemSpider [ 3]
24747352
ChEBI
CHEBI:63637 Y
ChEMBL [ 4]
CHEMBL1229517 Y
Hemijski podaci
Formula
C 23 H 18 Cl F 2 N 3 O 3 S
Mol. masa
489,922
SMILES
eMolekuli &PubHem
InChI
InChI=1/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28) Key: GPXBXXGIAQBQNI-UHFFFAOYNA-NY
Farmakokinetički podaci
Poluvreme eliminacije
57 h
Farmakoinformacioni podaci
Trudnoća
?
Pravni status
Način primene
Oralno
Vemurafenib jeorgansko jedinjenje ,koje sadrži 23atoma ugljenika i imamolekulsku masu od 489,922Da .[ 5] [ 6] [ 7]
↑ Li Q, Cheng T, Wang Y, Bryant SH (2010).„PubChem as a public resource for drug discovery.” .Drug Discov Today 15 (23-24): 1052-7.DOI :10.1016/j.drudis.2010.10.003 .PMID 20970519 . edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry 4 :217-241.DOI :10.1016/S1574-1400(08)00012-1 .
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010).„Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining” .J Cheminform 2 (1): 3.DOI :10.1186/1758-2946-2-3 .PMID 20331846 . edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”.Nucleic Acids Res 40 (Database issue): D1100-7.DOI :10.1093/nar/gkr777 .PMID 21948594 . edit
↑ Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24.PMID 23094782
↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs” .Nucleic Acids Res. 39 (Database issue): D1035-41.DOI :10.1093/nar/gkq1126 .PMC 3013709 .PMID 21059682 . edit
↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets” .Nucleic Acids Res 36 (Database issue): D901-6.DOI :10.1093/nar/gkm958 .PMC 2238889 .PMID 18048412 . edit
↑ Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods” .J. Phys. Chem. A 102 :3762-3772.DOI :10.1021/jp980230o .
↑ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices” .Chem Inf. Comput. Sci. 41 :1488-1493.DOI :10.1021/ci000392t .PMID 11749573 . edit
↑ Ertl P., Rohde B., Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties” .J. Med. Chem. 43 :3714-3717.DOI :10.1021/jm000942e .PMID 11020286 . edit